Division of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan.
School of Public Health, National Defense Medical Center, Taipei, Taiwan.
J Microbiol Immunol Infect. 2021 Oct;54(5):926-933. doi: 10.1016/j.jmii.2021.05.001. Epub 2021 Jun 24.
BACKGROUND/PURPOSE: Growth arrest-specific 6 (Gas6) protein is involved in cell proliferation, differentiation, adhesion, migration in response to inflammatory processes. Human immunodeficiency virus (HIV) infection induces a chronic inflammatory condition and combination of antiretroviral therapy improves immune function and decreases the inflammatory state. The aim of this study was to assess the implications of Gas6 in chronic inflammation status of HIV-infected patients undergoing different third regimens of antiretroviral therapy. The Gas6 may be a marker of chronic inflammation of HIV-infected patients.
A total of 356 adult males, including 258 HIV-infected patients and 98 healthy controls, were recruited. The demographic and clinical characteristics of the patients were collected. Laboratory assessment included hemogram, CD4 count, plasma HIV RNA load (PVL), hepatitis B and C viruses, and serum biochemistry. Plasma Gas6 concentrations were determined.
The values of Gas6 were lower in HIV patients compared to healthy subjects (14.3 ± 6.4 vs 21.5 ± 15.2, p = 0.01). HIV patients that received antiviral regimen with abacavir had similar Gas6 level than those who received antiviral regimens with tenofovir (14.3 ± 6.5 vs 13.8 ± 5.9, p = 0.99). HIV patients that received antiviral regimen with protease inhibitors (PIs) had lower Gas6 level (13.1 ± 3.5 vs 14.2 ± 6.6 vs 14.6 ± 6.5, p = 0.03) than those who received antiviral regimens with non-nucleoside reverse transcriptase inhibitors (nNRTIs) and integrase inhibitors (INSTIs), respectively.
Decreased plasma Gas6 concentrations were observed in HIV patients. Gas6 levels are associated with different third regimen of highly active antiretroviral therapy. Gas6 may represent a unique marker for assessing the chronic inflammation state difference among cART regimens in HIV patients.
背景/目的：生长停滞特异性蛋白 6（Gas6）参与细胞增殖、分化、黏附和迁移，以应对炎症过程。人类免疫缺陷病毒（HIV）感染会引起慢性炎症状态，联合抗逆转录病毒疗法可改善免疫功能并降低炎症状态。本研究旨在评估 Gas6 在接受不同第三类抗逆转录病毒疗法的 HIV 感染患者慢性炎症状态中的意义。Gas6 可能是 HIV 感染患者慢性炎症的标志物。
共招募了 356 名成年男性，包括 258 名 HIV 感染患者和 98 名健康对照者。收集了患者的人口统计学和临床特征。实验室评估包括血常规、CD4 计数、血浆 HIV RNA 载量（PVL）、乙型肝炎和丙型肝炎病毒以及血清生化。测定了血浆 Gas6 浓度。
与健康受试者相比，HIV 患者的 Gas6 值较低（14.3±6.4 比 21.5±15.2，p=0.01）。接受阿巴卡韦抗病毒方案治疗的 HIV 患者与接受替诺福韦抗病毒方案治疗的患者的 Gas6 水平相似（14.3±6.5 比 13.8±5.9，p=0.99）。接受蛋白酶抑制剂（PI）抗病毒方案治疗的 HIV 患者的 Gas6 水平较低（13.1±3.5 比 14.2±6.6 比 14.6±6.5，p=0.03）与接受非核苷类逆转录酶抑制剂（nNRTIs）和整合酶抑制剂（INSTIs）抗病毒方案治疗的患者相比。
HIV 患者的血浆 Gas6 浓度降低。Gas6 水平与不同的高效抗逆转录病毒治疗第三类方案相关。Gas6 可能代表一种评估 HIV 患者 cART 方案中慢性炎症状态差异的独特标志物。
